- Home
- PDCO vs AKRO Comparison
PDCO vs AKRO Comparison
Compare PDCO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCO
- AKRO
- Stock Information
- Founded
- PDCO 1877
- AKRO 2017
- Country
- PDCO United States
- AKRO United States
- Employees
- PDCO N/A
- AKRO N/A
- Industry
- PDCO Medical Specialities
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PDCO Health Care
- AKRO Health Care
- Exchange
- PDCO Nasdaq
- AKRO Nasdaq
- Market Cap
- PDCO 1.9B
- AKRO 2.2B
- IPO Year
- PDCO 1992
- AKRO 2019
- Fundamental
- Price
- PDCO $30.91
- AKRO $29.38
- Analyst Decision
- PDCO Hold
- AKRO Strong Buy
- Analyst Count
- PDCO 7
- AKRO 8
- Target Price
- PDCO $27.10
- AKRO $46.83
- AVG Volume (30 Days)
- PDCO 1.7M
- AKRO 535.2K
- Earning Date
- PDCO 12-05-2024
- AKRO 11-08-2024
- Dividend Yield
- PDCO 3.36%
- AKRO N/A
- EPS Growth
- PDCO N/A
- AKRO N/A
- EPS
- PDCO 1.72
- AKRO N/A
- Revenue
- PDCO $6,554,872,000.00
- AKRO N/A
- Revenue This Year
- PDCO $2.74
- AKRO N/A
- Revenue Next Year
- PDCO $3.25
- AKRO N/A
- P/E Ratio
- PDCO $17.96
- AKRO N/A
- Revenue Growth
- PDCO 0.05
- AKRO N/A
- 52 Week Low
- PDCO $19.45
- AKRO $15.32
- 52 Week High
- PDCO $31.79
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- PDCO 84.41
- AKRO 46.87
- Support Level
- PDCO $30.85
- AKRO $28.45
- Resistance Level
- PDCO $31.79
- AKRO $31.41
- Average True Range (ATR)
- PDCO 0.51
- AKRO 1.29
- MACD
- PDCO 0.91
- AKRO -0.15
- Stochastic Oscillator
- PDCO 92.02
- AKRO 37.64
About PDCO Patterson Companies Inc.
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.